Disrupting this glycosylation process, either by STT3 knockdown or pharmacological inhibition, leads to reduced PD-L1 levels in cancer stem cells (CSCs) and enhances their susceptibility to T-cell-mediated killing. This evidence concerns the gene CD274 and cancer.